<DOC>
	<DOC>NCT00646737</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and the tolerability of the substitution of mycophenolate mofetil for enteric-coated mycophenolate sodium in a population of stable renal transplant patients in Brazil, in a treatment regimen of immunosuppressants with tacrolimus and mycophenolate mofetil.</brief_summary>
	<brief_title>Conversion From Mycophenolate Mofetil to Mycophenolate Sodium in Renal Transplant</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Inclusion criteria Age between 18 and 65 years; First or second renal transplant within at least 12 weeks; Clinical stability, in the opinion of the investigator, during at least 8 weeks before inclusion in the study; Women of reproductive age must use contraceptive methods and present negative results in pregnancy test Serum creatinine &lt; 2.5 mg/dE; Patients in use of a immunosuppression regimen based on tacrolimus and mycophenolate mofetil (generic or not, in any dose), who present gastrointestinal symptoms Capacity to complete the study requirements; Exclusion criteria History of acute rejection, Proven or not by biopsy, in the last 2 months before the study; Recipients of multiple organs; Participation in any clinical investigation in the last 6 months before the present study; Thrombocytopenia (platelets &lt;75,00O/mm3), leucopenia (total leukocytes &lt;4,000/mm3)and/or anemia (hemoglobin &lt;9.0 gldL) before inclusion in the study; Clinically important disease, in the opinion of the investigator, including systemic infection, within 2 weeks before inclusion in the study; Presence of any neoplasia, current or past, except resected basal cell carcinoma; Any surgical or medical condition that could significantly alter the absorption, distribution, metabolism or excretion of medicines or that could put the patient in danger as a result of participation in the study; History of drug or alcohol abuse within previous 12 months of inclusion in the study, Current or prior use in the last 2 months of bile acidadsorbing resins(cholestyramine and colestipol).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Kidney transplantation</keyword>
	<keyword>conversion</keyword>
	<keyword>mycophenolate mofetil</keyword>
	<keyword>mycophenolate sodium,</keyword>
	<keyword>tacrolimus</keyword>
</DOC>